A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium

Trial Profile

A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Trebananib (Primary)
  • Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 May 2017 Status changed from active, no longer recruiting to completed.
    • 11 Jul 2015 Results published in the Gynecologic Oncology.
    • 06 Aug 2014 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top